{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:04:33Z","timestamp":1793210673184,"version":"4.5.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82000799"],"award-info":[{"award-number":["No. 82000799"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship between the use of GLP-1 receptor agonists and the occurrence of 6 kinds of thyroid disorders. We searched PubMed (MEDLINE), EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science from database inception to 31 October 2021 to identify eligible randomized controlled trials (RCTs). We performed meta-analysis using a random-effects model to calculate risk ratios (RRs) and 95% confidence intervals (CIs). A total of 45 trials were included in the meta-analysis. Compared with placebo or other interventions, GLP-1 receptor agonists\u2019 use showed an association with an increased risk of overall thyroid disorders (RR 1.28, 95% CI 1.03-1.60). However, GLP-1 receptor agonists had no significant effects on the occurrence of thyroid cancer (RR 1.30, 95% CI 0.86-1.97), hyperthyroidism (RR 1.19, 95% CI 0.61-2.35), hypothyroidism (RR 1.22, 95% CI 0.80-1.87), thyroiditis (RR 1.83, 95% CI 0.51-6.57), thyroid mass (RR 1.17, 95% CI 0.43-3.20), and goiter (RR 1.17, 95% CI 0.74-1.86). Subgroup analyses and meta-regression analyses showed that underlying diseases, type of control, and trial durations were not related to the effect of GLP-1 receptor agonists on overall thyroid disorders (all P <jats:sub>subgroup<\/jats:sub>\u2009&amp;gt; 0.05). In conclusion, GLP-1 receptor agonists did not increase or decrease the risk of thyroid cancer, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass and goiter. However, due to the low incidence of these diseases, these findings need to be examined further.<\/jats:p><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier: CRD42021289121.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.927859","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T05:28:51Z","timestamp":1657517331000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":126,"title":["Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Weiting","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2965","article-title":"The Relationship Between Thyroid Function and the Prevalence of Type 2 Diabetes Mellitus in Euthyroid Subjects","volume":"102","author":"Gu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.12.027","article-title":"Incidence and Prevalence of Thyroid Dysfunction in Type 1 Diabetes","volume":"30","author":"Nederstigt","year":"2016","journal-title":"J Diabetes Complications"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and Cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0396","article-title":"Diabetes and Thyroid Cancer Risk in the National Institutes of Health-AARP Diet and Health Study","volume":"21","author":"Aschebrook-Kilfoy","year":"2011","journal-title":"Thyroid"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and Cancer Risk: Emerging Biological Mechanisms and Perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00700-4","article-title":"Thyroid Dysfunction and Type 2 Diabetes Mellitus: Screening Strategies and Implications for Management","volume":"10","author":"Kalra","year":"2019","journal-title":"Diabetes Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-16-0450","article-title":"Metformin and Thyroid Disease","volume":"233","author":"Meng","year":"2017","journal-title":"J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7:8","DOI":"10.1186\/1471-2415-7-8","article-title":"Thiazolidinedione Induced Thyroid Associated Orbitopathy","volume":"4","author":"Lee","year":"2007","journal-title":"BMC Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/105072503322401032","article-title":"Peroxisome Proliferator-Activated Receptor-Gamma Gene Expression in Orbital Adipose\/Connective Tissues is Increased During the Active Stage of Graves' Ophthalmopathy","volume":"13","author":"Mimura","year":"2003","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021113-170315","article-title":"Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond","volume":"76","author":"Cho","year":"2014","journal-title":"Annu Rev Physiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s004410051371","article-title":"Correlation Between Gender and Spontaneous C-Cell Tumors in the Thyroid Gland of the Wistar Rat","volume":"297","author":"Mart\u00edn-Lacave","year":"1999","journal-title":"Cell Tissue Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/019262338901700205","article-title":"The Effects of Xenobiotics on the Structure and Function of Thyroid Follicular and C-Cells","volume":"17","author":"Capen","year":"1989","journal-title":"Toxicol Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1956","article-title":"No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial","volume":"41","author":"Heged\u00fcs","year":"2018","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 Inhibitors and GLP-1 Receptor Agonists: Established and Emerging Indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2855","article-title":"Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study","volume":"37","author":"Leiter","year":"2014","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14566","article-title":"Maintenance of Glycaemic Control With Liraglutide Versus Oral Antidiabetic Drugs as Add-on Therapies in Patients With Type 2 Diabetes Uncontrolled With Metformin Alone: A Randomized Clinical Trial in Primary Care (LIRA-PRIME)","volume":"24","author":"Unger","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and Safety of Liraglutide 3.0 Mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 Mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obes (Silver Spring)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 Years of Liraglutide Versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals With Prediabetes: A Randomised, Double-Blind Trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12674","article-title":"Efficacy and Safety of Liraglutide Versus Sitagliptin, Both in Combination With Metformin, in Chinese Patients With Type 2 Diabetes: A 26-Week, Open-Label, Randomized, Active Comparator Clinical Trial","volume":"18","author":"Zang","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3","article-title":"Efficacy and Safety of a Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Compared With its Components Given Alone: Results of a Phase 3, Open-Label, Randomised, 26-Week, Treat-to-Target Trial in Insulin-Naive Patients With Type 2 Diabetes","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ijo.2013.120","article-title":"Weight Maintenance and Additional Weight Loss With Liraglutide After Low-Calorie-Diet-Induced Weight Loss: The SCALE Maintenance Randomized Study","volume":"39","author":"Wadden","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003672551","article-title":"Efficacy and Safety of the Once-Daily Human GLP-1 Analogue, Liraglutide, vs Glibenclamide Monotherapy in Japanese Patients With Type 2 Diabetes","volume":"26","author":"Seino","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide Versus Sitagliptin for Patients With Type 2 Diabetes Who did Not Have Adequate Glycaemic Control With Metformin: A 26-Week, Randomised, Parallel-Group, Open-Label Trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 Study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide Versus Glimepiride Monotherapy for Type 2 Diabetes (LEAD-3 Mono): A Randomised, 52-Week, Phase III, Double-Blind, Parallel-Treatment Trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12414","article-title":"Efficacy and Tolerability of Albiglutide Versus Placebo or Pioglitazone Over 1\u2009Year in People With Type 2 Diabetes Currently Taking Metformin and Glimepiride: HARMONY 5","volume":"17","author":"Home","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0024","article-title":"HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin","volume":"37","author":"Ahr\u00e9n","year":"2014","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide Twice Daily Versus Glimepiride for Prevention of Glycaemic Deterioration in Patients With Type 2 Diabetes With Metformin Failure (EUREXA): An Open-Label, Randomised Controlled Trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and Safety of Exenatide Once Weekly Versus Sitagliptin or Pioglitazone as an Adjunct to Metformin for Treatment of Type 2 Diabetes (DURATION-2): A Randomised Trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13506","article-title":"Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients With Type 2 Diabetes Mellitus on Metformin and\/or a Sulphonylurea: A 52-Week Open-Label, Randomized Phase III Trial","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13340","article-title":"Efficacy and Safety of Dulaglutide Monotherapy Compared With Glimepiride in East-Asian Patients With Type 2 Diabetes in a Multicentre, Double-Blind, Randomized, Parallel-Arm, Active Comparator, Phase III Trial","volume":"20","author":"Chen","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12479","article-title":"Safety and Efficacy of Once-Weekly Dulaglutide Versus Sitagliptin After 2\u2009Years in Metformin-Treated Patients With Type 2 Diabetes (AWARD-5): A Randomized, Phase III Study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917","article-title":"Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients With Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12328","article-title":"Efficacy and Safety of Lixisenatide Once Daily vs. Placebo in People With Type 2 Diabetes Insufficiently Controlled on Metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabetes Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2006","article-title":"Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)","volume":"36","author":"Ahr\u00e9n","year":"2013","journal-title":"Diabetes Care"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454","article-title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-Week, Randomized, Placebo-Controlled Comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"B51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults With Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-Response, Efficacy, and Safety of Oral Semaglutide Monotherapy in Japanese Patients With Type 2 Diabetes (PIONEER 9): A 52-Week, Phase 2\/3a, Randomised, Controlled Trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"B56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral Semaglutide Versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized Clinical Trial Comparing the Efficacy and Safety of Oral Semaglutide Monotherapy With Placebo in Patients With Type 2 Diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity: A Randomised, Double-Blind, Placebo and Active Controlled, Dose-Ranging, Phase 2 Trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients With Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (With or Without Sulfonylureas) in Insulin-Naive Patients With Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre, Multinational, Phase 3a Trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes With Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B62","unstructured":"Effect of Liraglutide on Body Weight in Non-Diabetic Obese Subjects or Overweight Subjects With Co-Morbidities: SCALE\u2122-Obesity and Pre-Diabetes2011"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.07.024","article-title":"Effect of Exendin (Exenatide)\u2013GLP 1 Receptor Agonist on the Thyroid and Parathyroid Gland in a Rat Model","volume":"691","author":"Bulchandani","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jcpt.13259","article-title":"Glucagon-Like Peptide-1 Analogues and Thyroid Cancer: An Analysis of Cases Reported in the European Pharmacovigilance Database","volume":"46","author":"Mali","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.09.008","article-title":"A Meta-Analysis of Serious Adverse Events Reported With Exenatide and Liraglutide: Acute Pancreatitis and Cancer","volume":"98","author":"Alves","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice are Mediated via the GLP-1 Receptor and Not Associated With RET Activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2017.02.010","article-title":"Prediction of Thyroid C-Cell Carcinogenicity After Chronic Administration of GLP1-R Agonists in Rodents","volume":"320","author":"van den Brink","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland","volume":"97","author":"Gier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2014.29.4.536","article-title":"Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and its Clinicopathologic Significance","volume":"29","author":"Jung","year":"2014","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting","volume":"48","author":"K\u00f6rner","year":"2007","journal-title":"J Nucl Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/en.2012-2124","article-title":"The Glucagon-Like Peptide-1 Receptor\u2013or Not","volume":"154","author":"Pyke","year":"2013","journal-title":"Endocrinology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the Complexity of GLP-1 Action From Sites of Synthesis to Receptor Activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas","volume":"28","author":"Waser","year":"2015","journal-title":"Mod Pathol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S150701","article-title":"Effects of Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists on Proliferation and Cellular Energy Metabolism in Papillary Thyroid Cancer","volume":"10","author":"He","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2014.09.004","article-title":"Glucagon-Like Peptide-1 Stimulates Type 3 Iodothyronine Deiodinase Expression in a Mouse Insulinoma Cell Line","volume":"115","author":"Akiyama","year":"2014","journal-title":"Life Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1159\/000501895","article-title":"The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume","volume":"8","author":"Sencar","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Treatment: Are They All the Same","volume":"35","author":"Gentilella","year":"2019","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.927859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T05:28:59Z","timestamp":1657517339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.927859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":77,"alternative-id":["10.3389\/fendo.2022.927859"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.927859","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"article-number":"927859"}}